I only look at stocks that have the possibility to double over a twelve month period and stocks in which the risk/reward ratio payout is high. In addition I focus on swing trade opportunities. I focus more on valuations and risk/reward metrics as opposed to what make companies tick. I have been a professional investor for over 20 years and during the past several years an economics analyst and financial writer for capital.gr, the biggest economic news portal in Greece. I have managed money from time to time and have also done some seed venture capital projects in the past.
A little bit about me:
I hold two US issued software patents, one of which is issued internationally. I have 3+ decades experience as a software architect and 16 years as an intellectual property researcher specializing in security. I've delivered 1/2 a dozen shrink-wrap retail software packages to market and spent 3 years at Xerox's Palo Alto Research Center (PARC).
George Moriarty is Executive Editor and VP Content at Seeking Alpha. He joined the company in January 2012 as Managing Editor of Opinion & Analysis and works closely with CEO Eli Hoffmann and other company leaders on content and publishing initiatives for the Seeking Alpha contributor community. George has worked as a financial journalist and editor since 1997, most recently as Editor-in-Chief at Merrill Lynch Wealth Management Online Platforms. Prior to Merrill, he was Executive Editor at TheStreet.com. He lives in Bucks County, PA, with his wife, four young children and one dog. Please contact him via direct message.
Russ Koesterich, CFA, JD, Managing Director and head of Asset Allocation, is a member of the Global Allocation team within BlackRock's Multi-Asset Strategies Group. He serves as a member of BlackRock's Americas Executive Committee.
Mr. Koesterich's service with the firm dates back to 2005, including his years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Prior to his current role, Mr. Koesterich was BlackRock's Global Chief Investment Strategist and Chairman of the Investment Committee for the Model Portfolio Solutions business. Previously, he served as the Global Head of Investment Strategy for scientific active equities and as senior portfolio manager in the US Market Neutral Group. Prior to joining BGI, Mr. Koesterich was the Chief North American Strategist at State Street Bank and Trust. He began his investment career at Instinet Research Partners where he occupied several positions in research, including Director of Investment Strategy for both U.S. and European research, and Equity Analyst. He is a frequent contributor to financials news media and the author of two books, including his most recent "The Ten Trillion Dollar Gamble."
Mr. Koesterich earned a BA in history from Brandeis University, a JD from Boston College and an MBA from Columbia University. He is a CFA Charterholder.
Rocco Pendola is an associate editor at Seeking Alpha focusing on technology and the sectors it overlaps with.
In addition to technology, I am interested in dividend growth and income investing.
I make references to music I'm obsessed with (e.g., Old 97s, Elliott Smith, Bruce Springsteen) in my writing. If you notice any of these references, it makes me happy.
I'm managing editor for SA PRO. I work primarily on our PRO product, though also in support of our marketplace product and in a few other areas on the site. I'm always happy to hear from readers and contributors, whether to help with questions, hear your feedback, or learn how you're using the site. I've been working at SA since September 2012.
I've been investing for 6 years. I used to write articles for Seeking Alpha before becoming an editor (while I'm proud of the work I did, it probably would not have been up to our PRO standards, which is a good thing). I am probably one of SA's most frequent users, and have learned an immense amount from contributors, readers, and SA employees.
Beyond the market, I like reading, travel, writing, playing/writing/listening to music, and learning languages. Probably most relevant to ask me about SA, but you're welcome to get in touch on anything else as well.
TheStreetSweeper recently named Sonya Colberg as Senior Editor. About three years ago, she became senior investigative reporter of TheStreetSweeper, a website devoted to exposing fraud, shenanigans and lousy business practices of public companies. Sonya had worked more than two decades as an editor and reporter for two major newspapers, including the recent Warren Buffett acquisition, Tulsa World. Among others, the Associated Press, Great Plains Journalism Awards, The Gerald Loeb Awards and the Society of Professional Journalists have recognized Sonya’s investigative, feature, health, news and business stories. A fearless investigative reporter, Sonya loves nothing better than calling out the shysters and bumblers who quietly work to separate investors from their hard-earned money.
I graduated with a BSEE from NCSU. Following technology companies and developments is a hobby of mine when I have free time. A few years ago I started investing, and have tremendously enjoyed it. I try and share a unique view from an engineering vice an investor standpoint, and enjoy learning from others in the SA community.
George Dorgan had been one of the predictors of the financial tsunami of January 15, 2015. This is also visible in many posts in Seeking Alpha between 2012 and 2014. Very often he spoke about the impossibility of the peg and the strong Swiss economy.
He often criticized the - as for CHF - notoriously wrong bank research, in particular in the Seeking Alpha article:
The Swiss Franc, Pseudo-Mathematics and Financial Charlatanism
George lives in Zurich and knows well the Swiss mentality and the mindset of the Swiss National Bank (SNB) that is in line with supply-side and Austrian economics.
George is a heterodox economist and manages a very small private hedge fund on global macro basis following contrarian strategies.
Dorgan is largely an Austrian economist, supply sider and fierce advocat of deflation caused by technologic progress, free trade and the global distribution of labor.
He is against both the Keynesian mainstream and those Austrians that see the hyper-inflationary collapse coming. His ideas are also inspired by Minsky and Richard Koo, but he considers fiscal intervention only when private sector savings rates are rapidly increasing.
For Dorgan, GDP growth is currently not important, but a stabilisation of savings rates. Apart from some countries in Southern Europe, unemployment is extraordinarily low in the world, in particular in emerging and less privileged economies.
For him, the 2008 financial crisis was rather a balance of payments crisis of the United States and thanks to globalisation, only a very short-lived crisis.
Dorgan started up as quant programmer, worked at UBS and Reuters. He speaks nine languages including Russian.
He has a broad knowledge on (economic) history, law, computer science and business. He currrently manages Too Big To Fail projects in big Swiss banks.
His recent publications that were editor's picks in Seeking Alpha:
FX Rates, Contrarian Investment And The Misleading Concept Called GDP http://tinyurl.com/ortw73c
The Dollar, The ISM, Buy American And Irrational Exuberance http://tinyurl.com/o6q7qtg
Other useful contributions are the regularly updated:
What Drives Government Bond Yields? http://tinyurl.com/pnn3urn
The Six Major Fundamental Factors that Determine Gold and Silver Prices http://tinyurl.com/qxahse7
His Google Plus profile https://plus.google.com/u/0/+GeorgeMDorgan
and his Twitter account https://twitter.com/DorganG
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
I work on the crossroads of design, branding, consumer research and product development. Occasionally, I buy shares of companies, whose industry I understand or work in.
However, I take capitalism and its machinations with the necessary spoonful of quality Swedish stone salt.
I run my own consulting practice NT Advisors LLC, which serves companies in the technology and communications industries as well as private equity and venture capital firms. I am a former sell side equity research analyst in the technology sector for 18 years primarily at UBS. I was also the Global Technology Strategist at UBS from 2008-2012. During my career on Wall Street, I was voted to the Institutional Investor All-American Equity Research Team in 15 different years.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Value Digger holds MSc. in Electrical Engineering, speaks four languages (English, French, Greek, German) and has lived in the U.S. for many years. Also, he is a full-time investor and a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. His F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), Value Digger launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in his Premium Posts PROVE these high returns. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 50%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes to his publicly-available picks and his free Seeking Alpha articles, Value Digger is ranked in the TOP-50 with a success rate of over 80%, an average return per recommendation of over 30% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 9,000 financial experts worldwide.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Accountant by day, punk rock bass player by night
My purpose for submitting these articles is basically to expand upon my own stock research and analysis. I realize that as an accountant I probably have a biased opinion of the ease of combing through financial documents but I'd like to present this complex information in an easy to understand fashion for the masses.
I have been investing in Greek stock market since 2001 and I own a blog about it (Investorblog.gr) since 2007. My investing style is longterm and based in value investing and fundamentals. I do not take into account technical analysis. I can hold my position for years, but if conditions change or I have an early good performance, I have no problem to close my positions.
I have received my MS'c degree in Economics from University of Peloponeese, Greece (Mark: 9.1 , 3d Rank)
I retired as CEO of an Automotive Parts supplier, and manage an investment portfolio for myself and family. I have a BA in History from Royal Military College of Canada and an MBA from the University of Western Ontario. My first career was as a fighter pilot in the RCAF, and, following my MBA I joined McKinsey & Company, Inc. leaving them for Canadian GE. I left CGE as a Vice President in 1984 and founded The Enfield Corporation Limited ("Enfield") which grew from 243 employees in 1984 to over 10,000 in 1989 when Enfield was taken over and I was replaced as CEO. In 1989, I acquired control of Algonquin Mercantile Corporation, renamed Automodular Corporation in the late 1990's when I turned it to focus exclusively on automotive parts sub-assembly. Along the way, Algonquin turned a few ageing drug stores into Pharmx Rexall Drug Stores Ltd., sold to Katz group in 1997 and today a major Canadian drug store chain. I have been a private investor since 1971 both directly and through a private company controlled by myself and members of my family.
I am an equity analyst and founding member of a triple digit million dollar fund.
Oh, and I think technicals are nonsense.
...and no, the picture isn't me but a notable politician, and yes Mr. Samaras has been replaced!
I am fully accountable for the recommendations I make.... On my Instablog I give a recap of ALL picks and their performance
As a data analyst, Freddy Hutter of Trendlines Research provides guidance in chart format on the specialties of peak oil, realty bubbles, baseline GDP projections and election predictions. Virtually each day an update is published to the website's MemberVenue. All charts are made publicly available the site's FreeVenue after a 90-day exclusivity to subscribers.
TRENDLines coverage commenced in 1989, but Hutter's macro economic guidance goes back to 1971. Accurate and timely analysis includes the TRENDLines Recession Indicators (TRI) for Canada, China & USA; the Realty Bubble Monitor's tracking of housing bubbles in Australia, Canada, UK & USA; the Barrel Meter's tracking of price components for gasoline and crude oil along with 1/5/10/23-year crude price projections; and the PS2500's multi-century forecast for oil production & depletion; and the Debt Wall - USA 30-year Debt/Deficit projections. Randomly the firm provides c02 projections on the effects of fossil fuel contribution to climate change; and key international election forecasts.
As a contributor to the New Low Observer (http://www.newlowobserver.com/about-this-site), we intend to give new insights on a low risk approach to trading in dividend paying stocks for tax deferred accounts. The New Low Observer (http://www.newlowobserver.com/about-this-site) is not intended for regular or non-qualifying accounts however, the strategies and stocks mentioned can be used for non-qualifying accounts with the understanding of the consequences of potential short-term capital gains as well as the need for exceptional documentation for IRS purposes.
I have a professional background of working with the Federal Reserve Bank of San Francisco, Bear Stearns, Fannie Mae and Freddie Mac. Although I am an economist (and probably because of that fact), I am adept at being resourceful and thinking in a multidisciplinary fashion. For this reason, my professional experience only reflects a wide perspective that I have gained through the years and should not connote an air of authority.
Jeffrey Dow Jones is the managing editor for Alpine Advisor. He has previously worked for PaineWebber/UBS and Ford Motor Credit Company, and he spent the last decade co-managing a group of hedge funds. He holds a degree in Business Economics with a specialization in Computer Programming from The University of California - Los Angeles.
He publishes a free weekly newsletter at AlpineAdvisor.info.
ForexAbode.com is a leading Forex portal and provides free Forex trading analysis, forecast & strategies, free trading tools, education, Forex Blogs and Forex Forum. The growing popularity of ForexAbode is because of the diversified contents to help various levels of retail forex traders.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register for free @ bretjenseninvests.com